Imatinib Krka D.D.

Imatinib, the active ingredient in Imatinib Krka D.D., is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats certain cancers such as chronic myeloid leukemia, gastrointestinal stromal tumor and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Imatinib Krka D.D. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells that depend on specific tyrosine‑kinase signaling pathways. It is indicated for the following conditions: - Chronic myeloid leukemia (CML): improves survival by inhibiting BCR‑ABL kinase activity. - Gastrointestinal stromal tumor (GIST): reduces tumor growth through c‑KIT inhibition. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by blocking BCR‑ABL driven proliferation.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: intermittent painful contractions. - Fatigue: reduced energy levels. - Diarrhea: loose stools, sometimes watery. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced cardiac output. - Pulmonary hypertension: increased pressure in lung arteries. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.

Patients should be monitored closely for safety concerns during therapy. - Blood count monitoring: perform regular CBC to detect cytopenias. - Liver function assessment: check transaminases before and during treatment. - Cardiac evaluation: baseline and periodic ECG for patients with cardiac risk. - Hypersensitivity avoidance: discontinue if severe allergic reaction occurs. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Imatinib may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: potential increase in serum digoxin concentrations. - Live vaccines: reduced vaccine efficacy; consider timing relative to therapy.